Endpoints for Neuroprotection in Glaucoma Trials, Upcoming Webinar Hosted by Xtalks
TORONTO, Nov. 22, 2023 /PRNewswire-PRWeb/ -- Join us for a cutting-edge webinar delving into innovative clinical approaches and endpoints for new glaucoma treatments. Today, intraocular pressure (IOP) lowering therapies are currently the only proven neuroprotective therapies for glaucoma. While IOP therapies and devices are highly prevalent in use, unfortunately even with these treatments up to one in four patients still experience blindness in at least one eye. With disease progression still often significant despite the application of these therapies, this is an opportunity for new therapeutic entries. As companies explore new therapies to provide neuroprotection (preserving neuronal integrity) or even neuroenhancement (improving neuronal function), finding the right clinical approaches and endpoints to prove efficacy is paramount.